Five Winners And One Loser From Medicine’s Big Meeting About Blood

0 Comment

Within the last a couple of days, doctors who treat blood diseases have been meeting with the annual convention in the American Society of Hematology in Atlanta. There?¡¥s plenty of innovation coursing through seo. Here’s strategies for companies who’re being bold.

Bluebird Bio Hits A great Slam

Researchers working with Cambridge, Mass.-based gene therapy startup Bluebird Bio presented three eye-catching studies: of your new form of cancer-killing cell, referred to as a CAR-T, that is certainly targeted against multiple myeloma of an gene therapy for beta thalassemia and of another gene therapy for sickle cell anemia.

CAR-T’s are hot now Novartis and Gilead Sciences are jockeying for position using rival CAR-T products  but so far they may be limited to types of leukemia and lymphoma. Bluebird’s bb2121, being developed with biotech giant Celgene, targets a protein called BCMA that is certainly seen on myeloma cells. Patients ended up failed by up to seven previous drugs. Yet 17 of 18 saw their cancer retreat, as well as in 10, it gave the impression to disappear ¡§C termed as a complete response or even an unconfirmed complete response.
Effects were equally encouraging for the new manufacturing process for BlueBird’s answer to beta thalassemia, another blood disease. All three patients treated for more than six months could actually go without blood transfusions, and 2 had normal hemoglobin levels. Though the most encouraging news may have been in sickle cell. Bluebird had generated excitement with early results for an individual sickle cell patient and after that treating seven more patients didn’t show a similar benefit. Now, two patients helped by BlueBird’s new manufacturing process are showing equally good results. Okay, guys. Let’s see seven more.

Two different gene therapy products showed promise for potentially curing hemophilia A, the commonest type of the genetic illness that causes uncontrolled bleeding. BioMarin, of Novato, Calif., is in the clear lead. Spark Therapeutics presented a unique data this morning. A large controversy: how high should amounts of clotting element in the blood get BioMarin is pushing for higher levels, even with its lower dose; Spark appears to be more conservative. Spark’s data also look volatile, and it is timeline is behind BioMarin’s, which makes it one of several big stock trading game losers from the meeting, featuring its shares dropping 20% noisy . morning trading. Read about BioMarin here, and Spark here.


Leave a Reply

Your email address will not be published. Required fields are marked *